Patrick Baumhof, Regina Heidenreich, Birgit Scheel, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek
CureVac GmbH, Tübingen, 72076, Germany
CureVac has developed a novel nanoparticular RNA-based adjuvant formulation with strong immunostimulatory properties. RNAdjuvant® can be combined with different antigenic formats, like recombinant proteins and peptides, resulting in dramatically increased immunogenicity of these vaccines.
Due to its inherent charge and size, the RNAdjuvant® specifically targets professional and semi-professional antigen presenting cells. This specific mode of cell targeting might explain the ability of RNAdjuvant® to elicit ‘balanced immune responses’ comprising humoral and cellular effector responses and, importantly, memory responses.